Halozyme Therapeutics HALO Debt-to-assets
Debt-to-assets at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's debt-to-assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's debt-to-assets?
- Halozyme Therapeutics (HALO) reported debt-to-assets of 0.8× in Q1 2026.
- How has Halozyme Therapeutics's debt-to-assets changed year-over-year?
- Halozyme Therapeutics's debt-to-assets increased by 16.4% year-over-year, from 0.7× to 0.8×.
- What is the long-term trend for Halozyme Therapeutics's debt-to-assets?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's debt-to-assets has grown at a 4.5% compound annual growth rate (CAGR), from 0.7× to 0.9×.
- What does debt-to-assets mean?
- What fraction of everything the company owns is funded by debt.
- How do you interpret debt-to-assets?
- A lower ratio indicates a more conservatively financed balance sheet. Rising debt-to-assets over time signals increasing financial risk.
- How does debt-to-assets compare across companies?
- Comparable within an industry; bounded between 0 and 1 for most non-financials, which makes cross-company reads cleaner than debt-to-equity.